“Purpose of reviewJust as lumpectomy for breast


“Purpose of reviewJust as lumpectomy for breast Proteasome inhibitor drugs cancer aims at achieving oncological control with maximal tissue preservation, the concept of focal therapy for prostate cancer has evolved with the aim of controlling disease while preserving urinary and erectile function. Our review aims at describing the evolution of focal therapy in time and the resulting advances in patient selection.Recent findingsOriginally, focal therapy was developed as an alternative to active surveillance for men

with low-risk disease and a minimal burden of cancer. However, with improvement of the diagnostic technologies, the entry criteria for this therapeutic approach are broadening. Since its introduction, focal therapy has evolved from ablation of half or three-quarters of the prostate in

men with low-risk disease to only selected cancer foci even if they present with Gleason pattern 4. This development has become possible because of a better understanding of the biology of the index lesion(s) and the improvement of biopsy techniques. Candidates were selected at first with conventional transrectal random prostate biopsies. To overcome the sampling bias of standard techniques, a more thorough multicore sampling utilizing transperineal three-dimensional template mapping biopsies was developed. Today, advances in multiparametric MRI allow for detection and targeted biopsies of high-grade and high-volume lesions.SummaryIn Crenolanib price light of the less stringent selection criteria, enrollment for focal therapy protocols should encourage patient education on the need of possible subsequent cycles of ablation as well as the need for surveillance of the untreated prostatic tissue, Dinaciclib supplier as prostate cancer is transformed into a chronic, manageable condition.”
“Background: Because neonatal herpes simplex virus (NHSV) infection is difficult to diagnose,

there has been a move towards using more empiric acyclovir (ACV). Objective: The purpose of this study was to review the use of ACV to optimize future management of NHSV. Methods: Charts were reviewed for infants started on intravenous ACV up to day 43 of life – January 2001 through February 2007- at five hospitals in Edmonton and Calgary. Results: ACV was started for possible (N = 115) or proven (N = 3) herpes simplex virus (HSV) infection. Six of the infants with possible HSV infection later had proven HSV infection. Seizures (34%), hemodynamic instability (29%) and skin lesions (24%) were the most common indications for ACV. Among the 118 infants, 106 (90%) had cerebrospinal fluid obtained and 82 (69%) had at least one surface swab for HSV but 4 (3%) had no specimens submitted for HSV detection. ACV was continued for 3.9 +/- 3.5 days in the infants with no proven HSV disease. Possible nephrotoxicity from ACV was recorded in 3 of these 109 infants and in none of the infants with proven HSV disease.

Comments are closed.